CC
APGE

Caxton Corporation’s Apogee Therapeutics APGE Stock Holding History

Caxton Corporation’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-7,353
Closed -$205K – 13
2023
Q4 		$205K Sell
7,353
-5,119
-41% -$103K 1.11% 7
2023
Q3 		$266K Buy
+12,472
New +$275K 1.01% 5

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Caxton Corporation's APGE Position: Q1 2024 in Review

Caxton Corporation sold out of Apogee Therapeutics (APGE) in Q1 2024, closing a stake of 7,353 shares — an estimated $205K sold.

Caxton Corporation first reported a position in APGE in Q3 2023 and held it in 2 quarters. The position peaked at $266K in Q3 2023. 139 funds tracked by Wall St. Rank hold APGE as of Q1 2024.

  • Caxton Corporation reported no remaining Apogee Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Caxton Corporation sold 7,353 Apogee Therapeutics shares in Q1 2024, an estimated $205K.
  • Caxton Corporation first reported a position in Apogee Therapeutics in Q3 2023 and held it in 2 quarters.
  • Caxton Corporation's Apogee Therapeutics position peaked at $266K in Q3 2023.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2024.

Based on Caxton Corporation's 13F filing for Q1 2024, filed 15 May 2024.